Rocket Pharmaceuticals Stock Debt To Equity
| RCKT Stock | USD 14.39 0.19 1.34% |
Rocket Pharmaceuticals fundamentals help investors to digest information that contributes to Rocket Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rocket Stock. The fundamental analysis module provides a way to measure Rocket Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rocket Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.05 | 0.05 |
Rocket | Debt To Equity |
Rocket Pharmaceuticals Company Debt To Equity Analysis
Rocket Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Rocket Pharmaceuticals Debt To Equity | 0.06 % |
Most of Rocket Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rocket Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rocket Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Rocket Pharmaceuticals is extremely important. It helps to project a fair market value of Rocket Stock properly, considering its historical fundamentals such as Debt To Equity. Since Rocket Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rocket Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rocket Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Rocket Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Rocket Pharmaceuticals has a Debt To Equity of 0.057%. This is 99.89% lower than that of the Biotechnology sector and 99.71% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.88% higher than that of the company.
Rocket Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rocket Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rocket Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rocket Pharmaceuticals by comparing valuation metrics of similar companies.Rocket Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Rocket Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Rocket Pharmaceuticals from analyzing Rocket Pharmaceuticals' financial statements. These drivers represent accounts that assess Rocket Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Rocket Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.1B | 3.0B | 1.4B | 1.3B | 2.5B | 2.6B | |
| Enterprise Value | 977.5M | 2.8B | 1.2B | 1.2B | 2.5B | 2.6B |
Rocket Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rocket Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rocket Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rocket Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 1.08 B | ||||
| Shares Outstanding | 91.16 M | ||||
| Shares Owned By Insiders | 3.38 % | ||||
| Shares Owned By Institutions | 96.62 % | ||||
| Number Of Shares Shorted | 11.09 M | ||||
| Price To Book | 3.93 X | ||||
| EBITDA | (236.62 M) | ||||
| Net Income | (245.59 M) | ||||
| Cash And Equivalents | 321.37 M | ||||
| Cash Per Share | 4.87 X | ||||
| Total Debt | 25.04 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 13.41 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (194.92 M) | ||||
| Short Ratio | 15.00 X | ||||
| Earnings Per Share | (2.73) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 46.79 | ||||
| Number Of Employees | 268 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 1.29 B | ||||
| Total Asset | 566.34 M | ||||
| Retained Earnings | (959.37 M) | ||||
| Working Capital | 329.72 M | ||||
| Net Asset | 566.34 M |
About Rocket Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rocket Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.